ArticleJournal of pain and symptom management2026
Racial Disparities in Non-Stigmatized Supportive Care Medication Use in Pancreatic Cancer.
Article in Journal of pain and symptom management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPancreatic cancer (PC) is associated with a high symptom burden that contributes to reduced health-related quality of life (HRQoL) and adverse clinical outcomes. Supportive care medications (SCMs) are essential for symptom management. Prior studies have documented racial disparities in the use of stigmatized medication classes such as opioids and psychotropics. However, less is known about whether similar disparities exist for non-stigmatized SCMs. This study examined racial and ethnic differences in the use of non-stigmatized SCMs during end-of-life care among patients with PC.
methodsWe conducted a retrospective cohort study using SEER-Medicare data from 2005 to 2017. Patients with PC who had continuous Medicare Parts A, B, and D coverage and died within 12 months of diagnosis were included. SCM use was defined as at least one outpatient prescription claim for antiemetics, appetite stimulants, cognitive aids, headache aids, or sleep aids. Multivariable logistic regression models were used to estimate adjusted odds ratios (aORs) for SCM use by race and ethnicity, controlling for demographic, clinical, and socioeconomic factors.
resultsThe final cohort included 74,309 patients (Non-Hispanic White: 72.5%, Black: 11.0%, Hispanic: 9.6%, Asian/Pacific Islander: 6.6%). Compared to Non-Hispanic White patients, Black patients had lower use of antiemetics (aOR 0.77; 95% CI: 0.73-0.81), headache aids (aOR 0.68; 95% CI: 0.63-0.74), and sleep aids (aOR 0.68; 95% CI: 0.64-0.72), but higher use of appetite stimulants (aOR 1.06; 95% CI: 1.01-1.11) and cognitive aids (aOR 1.38; 95% CI: 1.25-1.53). Similar patterns were observed for other racial and ethnic minority groups, though findings varied by medication class.
conclusionRacial and ethnic disparities persist in the use of non-stigmatized SCMs among patients with PC at the end of life. These findings extend prior evidence on inequities in cancer symptom management and underscore the need for interventions that promote equitable access to SCMs across diverse populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.